ALKS
Alkermes plc NASDAQ Listed Jul 16, 1991$35.40
Mkt Cap $5.9B
52w Low $25.17
89.5% of range
52w High $36.60
50d MA $31.58
200d MA $30.29
P/E (TTM)
22.7x
EV/EBITDA
10.8x
P/B
3.0x
Debt/Equity
0.0x
ROE
13.3%
P/FCF
9.6x
RSI (14)
—
ATR (14)
—
Beta
0.39
50d MA
$31.58
200d MA
$30.29
Avg Volume
2.3M
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Connaught House · Dublin, L2 4 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | 0.43 | 0.34 | -20.9% | 33.39 | -2.7% | -7.0% | -1.0% | -2.0% | +0.5% | -3.5% | — |
| Oct 28, 2025 | BMO | 0.42 | 0.49 | +16.7% | 29.72 | +1.8% | +4.3% | +1.5% | -2.0% | -0.4% | -1.7% | — |
| Jul 29, 2025 | BMO | 0.41 | 0.52 | +26.8% | 26.15 | +5.2% | +3.3% | +3.4% | -5.2% | +0.2% | +0.3% | — |
| May 1, 2025 | BMO | 0.25 | 0.13 | -48.9% | 28.77 | -0.1% | +6.3% | +3.9% | -1.2% | -3.3% | +0.1% | — |
| Feb 12, 2025 | BMO | 0.81 | 1.04 | +28.4% | 31.96 | +1.3% | +4.8% | +7.5% | -0.3% | +0.0% | -0.2% | — |
| Oct 24, 2024 | BMO | 0.74 | 0.72 | -2.7% | 27.85 | -3.0% | -3.6% | -2.8% | +1.7% | -0.3% | -0.5% | — |
| Jul 24, 2024 | BMO | 0.70 | 0.70 | +0.0% | 25.00 | +7.6% | +6.0% | +5.8% | -0.6% | +0.1% | -1.0% | — |
| May 1, 2024 | BMO | 0.59 | 0.44 | -25.4% | 24.54 | -2.8% | -2.2% | -0.6% | +0.8% | +0.2% | +2.0% | — |
| Feb 15, 2024 | BMO | 0.46 | 0.48 | +4.3% | 27.99 | +2.7% | +16.3% | -1.2% | -5.6% | -4.0% | -0.9% | — |
| Oct 25, 2023 | BMO | 0.44 | 0.64 | +45.5% | 25.32 | -6.9% | -7.4% | +5.3% | -3.2% | +1.7% | -0.5% | — |
| Jul 26, 2023 | BMO | 0.48 | 0.55 | +14.6% | 30.84 | -2.3% | -2.6% | +0.8% | -5.0% | +1.8% | -2.5% | — |
| Apr 26, 2023 | BMO | 0.00 | 0.01 | +172.6% | 30.51 | -2.5% | -7.0% | -0.1% | +0.7% | +0.3% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | BofA Securities | Maintains | Neutral → Neutral | — | $34.77 | $35.00 | +0.7% | +0.4% | -4.5% | +1.2% | +0.4% | -1.9% |
| Mar 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.71 | $27.39 | -1.2% | +2.5% | +3.4% | +1.9% | -1.8% | +2.6% |
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.04 | $31.06 | +0.1% | -1.0% | -2.1% | +0.5% | -3.5% | +0.3% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $31.04 | $31.06 | +0.1% | -1.0% | -2.1% | +0.5% | -3.5% | +0.3% |
| Feb 20 | BofA Securities | Maintains | Neutral → Neutral | — | $32.00 | $31.80 | -0.6% | -0.3% | +0.9% | +3.7% | -7.0% | -1.0% |
| Nov 17 | Truist | Maintains | Buy → Buy | — | $29.04 | $29.36 | +1.1% | +1.0% | -0.2% | -1.9% | -1.7% | +1.5% |
| Nov 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.41 | $30.60 | -2.6% | -1.3% | -6.4% | +1.0% | -0.2% | -1.9% |
| Nov 13 | Deutsche Bank | Maintains | Buy → Buy | — | $31.41 | $30.60 | -2.6% | -1.3% | -6.4% | +1.0% | -0.2% | -1.9% |
| Nov 12 | Truist | Maintains | Buy → Buy | — | $33.81 | $27.97 | -17.3% | -7.1% | -1.3% | -6.4% | +1.0% | -0.2% |
| Oct 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.00 | $31.00 | +0.0% | +1.5% | -2.0% | -0.4% | -1.7% | +0.7% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $31.00 | $31.00 | +0.0% | +1.5% | -2.0% | -0.4% | -1.7% | +0.7% |
| Oct 27 | Mizuho | Maintains | Outperform → Outperform | — | $29.80 | $30.05 | +0.8% | -0.3% | +4.3% | +1.5% | -2.0% | -0.4% |
| Oct 23 | RBC Capital | Maintains | Outperform → Outperform | — | $31.09 | $31.22 | +0.4% | -3.4% | -0.8% | -0.3% | +4.3% | +1.5% |
| Oct 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $31.09 | $31.22 | +0.4% | -3.4% | -0.8% | -0.3% | +4.3% | +1.5% |
| Sep 26 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $27.13 | $28.20 | +3.9% | +2.8% | +4.1% | +3.3% | +2.2% | +2.0% |
| Sep 9 | JP Morgan | Maintains | Neutral → Neutral | — | $28.45 | $28.56 | +0.4% | -2.1% | -3.3% | +2.9% | -2.7% | -1.7% |
| Sep 9 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $28.45 | $28.56 | +0.4% | -2.1% | -3.3% | +2.9% | -2.7% | -1.7% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $27.00 | $27.40 | +1.5% | +3.4% | -5.2% | +0.2% | +0.3% | -0.2% |
| Jul 29 | Needham | Maintains | Buy → Buy | — | $26.15 | $27.50 | +5.2% | +3.3% | +3.4% | -5.2% | +0.2% | +0.3% |
| Jul 21 | Needham | Maintains | Buy → Buy | — | $29.22 | $28.98 | -0.8% | -8.8% | +1.4% | +0.6% | -2.4% | -1.5% |
| Jul 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $29.22 | $28.98 | -0.8% | -8.8% | +1.4% | +0.6% | -2.4% | -1.5% |
| Jun 17 | UBS | Upgrade | Neutral → Buy | — | $29.42 | $30.24 | +2.8% | +1.2% | -1.5% | -0.8% | +0.6% | +0.3% |
| May 2 | Baird | Maintains | Outperform → Outperform | — | $30.58 | $31.02 | +1.4% | +3.9% | -1.2% | -3.3% | +0.1% | +0.0% |
| May 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $30.58 | $31.02 | +1.4% | +3.9% | -1.2% | -3.3% | +0.1% | +0.0% |
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $27.84 | $27.93 | +0.3% | +0.3% | +3.1% | +0.0% | +6.3% | +3.9% |
| Mar 27 | Deutsche Bank | Maintains | Buy → Buy | — | $33.69 | $34.41 | +2.1% | -0.5% | -1.0% | -0.6% | -1.5% | +0.4% |
| Mar 4 | UBS | Upgrade | Sell → Neutral | — | $34.11 | $34.68 | +1.7% | +3.8% | -0.3% | -1.8% | -0.9% | +2.6% |
| Feb 14 | Goldman Sachs | Maintains | Buy → Buy | — | $36.00 | $36.06 | +0.2% | -0.3% | +0.0% | -0.2% | -0.9% | -0.5% |
| Feb 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $33.50 | $33.62 | +0.4% | +7.5% | -0.3% | +0.0% | -0.2% | -0.9% |
| Nov 13 | Mizuho | Maintains | Outperform → Outperform | — | $29.23 | $29.23 | +0.0% | +0.0% | -3.0% | -0.6% | -2.3% | -0.3% |
| Nov 5 | Stifel | Upgrade | Hold → Buy | — | $26.59 | $27.87 | +4.8% | +6.7% | +3.2% | -1.1% | -0.4% | +4.2% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | JP Morgan | Maintains | Neutral → Neutral | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | Goldman Sachs | Maintains | Buy → Buy | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $28.91 | $28.63 | -1.0% | +0.5% | -3.6% | +0.3% | +0.9% | -0.2% |
| Oct 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.59 | $26.42 | -0.6% | +2.9% | +5.6% | +0.5% | -3.6% | +0.3% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.66 | $27.78 | +0.4% | +0.6% | -0.3% | +0.3% | +1.9% | +0.7% |
| Jul 25 | Baird | Maintains | Outperform → Outperform | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | JP Morgan | Maintains | Neutral → Neutral | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 15 | JP Morgan | Maintains | Neutral → Neutral | — | $23.57 | $23.60 | +0.1% | -0.8% | +5.3% | +0.0% | +0.2% | +0.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.06 | $24.14 | +0.3% | -1.7% | +2.3% | -0.1% | -1.0% | +1.2% |
| May 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.21 | $24.29 | +0.3% | -0.9% | +0.1% | -1.1% | -1.9% | -0.3% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.01 | $23.87 | -0.6% | -0.6% | +0.8% | +0.2% | +2.0% | -2.0% |
| Apr 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $23.76 | $23.65 | -0.5% | +0.4% | +0.9% | +0.8% | +1.6% | -0.9% |
| Apr 9 | Jefferies | Maintains | Buy → Buy | — | $25.93 | $27.29 | +5.2% | +3.1% | -2.2% | -4.4% | -2.3% | -1.6% |
| Apr 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.07 | $27.13 | +0.2% | +0.6% | -1.7% | -1.6% | -2.0% | +1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Gaffin David JosephOff | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $33.20 | $68K | 231,558 | +6.09% | — |
| May 1, 2026 | Hopkinson Craig C.Off | EVP R&D, Chief Medical Officer | Sell | 9,000 | $33.40 | $301K | 81,389 | +2.37% | -1.16% |
8-K · 2.02
!! High
Alkermes plc -- 8-K 2.02: Earnings Results
Alkermes announced Q1 2026 results and revised full-year 2026 guidance, with updated financial expectations providing investors clarity on the company's performance trajectory and anticipated outcomes.
May 5
8-K
Alkermes Inc. plc -- 8-K Filing
Alkermes plc filed its Q4 2025 financial results, providing investors with year-end performance metrics and guidance for the biopharmaceutical company's future operations.
Feb 25
8-K · 5.02
!!! Very High
Alkermes Inc. plc -- 8-K 5.02: Executive Change
Alkermes appointed Blair C. Jackson as CEO effective July 31, 2026, signaling potential strategic leadership changes that investors should monitor for impact on company direction.
Feb 25
8-K · 2.01
!!! Very High
Alkermes Inc. plc -- 8-K 2.01: Acquisition Completed
Alkermes completed its acquisition of Avadel Pharmaceuticals, expanding its specialty pharma portfolio and potentially enhancing revenue streams through Avadel's existing product lineup and pipeline.
Feb 12
Data updated apr 24, 2026 5:19pm
· Source: massive.com